Serum galectin-3 as a potential marker for gastric cancer

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 755-760

  Cheng, Daye ^a   Liang, Bin ^a   Li, Yunhui ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

Diagnosis; Galectin 3; Serum; Stomach Neoplasms

Indexed keywords

GALECTIN 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; BLOOD; CASE CONTROL STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; GALECTIN 3; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ROC CURVE; STOMACH NEOPLASMS;

EID: 84924719480     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892386     Document Type: Article

References (37)

1. Leung WK, Wu MS, Kakugawa Y et al: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol, 2008; 9: 279–87.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Cancer J Clin, 2005; 55: 74–108.
3. Prognostic role of MicroRNA-21 in gastric cancer: a meta-analysis. Med Sci Monit, 2015; 21: 1668–74.
4. Yuan D, Zhu K, Dang C et al: NS5ATP9 mRNA levels in peripheral blood mononuclear cells predict prognosis in patients with gastric cancer. Med Oncol, 2014; 31: 106.
5. Tan YK, Fielding JW: Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol, 2006; 18: 821–29.
6. Barondes SH, Castronovo V, Cooper DN et al: Galectins: a family of animal beta-galactoside-binding lectins. Cell, 1994; 76: 597–98.
7. Funasaka T, Raz A, Nangia-Makker P: Nuclear transport of galectin-3 and its therapeutic implications. Semin Cancer Biol, 2014; 27C: 30–38.
8. Righi A, Jin L, Zhang S et al: Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol, 2010; 326: 8–14.
9. Wang JL, Werner EA, Laing JG, Patterson RJ: Nuclear and cytoplasmic localization of a lectin-ribonucleoprotein complex. Biochem Soc Trans, 1992; 20: 269–74.
10. Sakaki M, Oka N, Nakanishi R et al: Serum level of galectin-3 in human bladder cancer. J Med Invest, 2008; 55: 127–32.
11. Gao X, Balan V, Tai G, Raz A: Galectin-3 induces cell migration via a calcium- sensitive MAPK/ERK1/2 pathway. Oncotarget, 2014; 5(8): 2077–84.
12. Inohara H, Akahani S, Koths K, Raz A: Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res, 1996; 56: 4530–34.
13. Chen HY, Fermin A, Vardhana S et al: Galectin-3 negatively regulates TCRmediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci USA, 2009; 106: 14496–501.
14. Yang RY, Liu FT: Galectins in cell growth and apoptosis. Cell Mol Life Sci, 2003; 60: 267–76.
15. D’Haene N, Sauvage S, Maris C et al: VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis. PLoS One, 2013; 8: e67029.
16. Nangia-Makker P, Nakahara S, Hogan V, Raz A: Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr, 2007; 39:79–84.
17. Schoeppner HL, Raz A, Ho SB, Bresalier RS: Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer, 1995; 75: 2818–26.
18. Berberat PO, Friess H, Wang L et al: Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem, 2001; 49: 539–49.
19. Orlandi F, Saggiorato E, Pivano G et al: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res, 1998; 58: 3015–20.
20. Yamaki S, Fujii T, Yajima R et al: Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today, 2013; 43: 901–5.
21. Miyazaki J, Hokari R, Kato S et al: Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep, 2002; 9: 1307–12.
22. Iacovazzi PA, Notarnicola M, Caruso MG et al: Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol, 2010; 32: 160–64.
23. Iurisci I, Tinari N, Natoli C et al: Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res, 2000; 6: 1389–93.
24. Xie L, Ni WK, Chen XD et al: The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol, 2012; 138: 1035–43.
25. Isic T, Savin S, Cvejic D et al: Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J Cancer Res Clin Oncol, 2010; 136: 1805–12.
26. Balan V, Wang Y, Nangia-Makker P et al: Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget, 2013; 4: 542–49.
27. Saussez S, Lorfevre F, Lequeux T et al: The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol, 2008; 44: 86–93.
28. Baldus SE, Zirbes TK, Weingarten M et al: Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol, 2000; 21: 258–66.
29. Leal MF, Calcagno DQ, Chung J et al: Deregulated expression of annexin- A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med, 2014 [Epub ahead of print].
30. Okada K, Shimura T, Suehiro T et al: Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res, 2006; 26: 1369–76.
31. Newlaczyl AU, Yu LG: Galectin-3 – a jack-of-all-trades in cancer. Cancer Lett, 2011; 313: 123–28.
32. Kim SJ, Choi IJ, Cheong TC et al: Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology, 2010; 138: 1035–45 e1–2.
33. Ochieng J, Leite-Browning ML, Warfield P: Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun, 1998; 246: 788–91.
34. Cheong TC, Shin JY, Chun KH: Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci, 2010; 101: 94–102.
35. Chen C, Duckworth CA, Zhao Q et al: Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res, 2013; 19: 1693–704.
36. Partyka R, Gonciarz M, Jalowiecki P et al: VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue. Med Sci Monit, 2012; 18(4): BR130–34.
37. Markowska AI, Liu FT, Panjwani N: Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med, 2010; 207: 1981–93.